Mariana Oncology

Thanksgiving is the perfect time to express our gratitude for our dedicated team, partners, and the people living with cancer that we serve. Your support and collaboration inspire us every day as we strive to advance radiotherapy and improve cancer care. As you gather with loved ones, we encourage you to take a moment to reflect on what you’re thankful for. Wising you a joyful and peaceful Thanksgiving from all of us at #TeamMariana! #Thanksgiving #Gratitude #Oncology

Radioligand therapies are an emerging treatment modality that pairs the cancer-killing power of radiotherapy with the precision of targeted therapies. These treatments comprise a targeting compound or ligand designed to bind to a specific cancer marker, a radioisotope that emits radiation, and a chelator that strongly binds to and protects the radioisotope. The ligand directs the therapy to the target cancer cells and radiation emitted from the radioisotope causes critical damage to cancer cells. This targeted approach is designed to limit the impact of treatment on healthy cells, offering potential to improve the experience of treatment for patients. Learn more about our approach to radioligand therapy: https://brnw.ch/21wOXh0

#ICYMI: In October, we presented new preclinical data at #ENA24 that demonstrate the activity of our DLL3-targeted radioligand therapy in several tumor models, including those with low DLL3 expression levels, supporting its potential to address a range of solid tumors (Poster ENA24-152). #RLT #radioligandtherapy #oncology

Lung cancer is one of the most common cancers worldwide, with a significant unmet need for safe and effective treatment options. At Mariana Oncology, we are committed to advancing novel #radioligandtherapies (RLTs) with the potential to improve the experience of cancer treatment for patients with lung cancer and other solid tumors. Our portfolio of RLTs is designed to selectively address innovative cancer targets and deliver radiation directly to cancer cells, minimizing damage to healthy tissues. Learn more about lung cancer and how you can get involved this Lung Cancer Awareness Month: https://brnw.ch/21wOKjC #LCAM #LungCancerAwareness #CancerResearch

Our team enjoyed taking in pioneering research and engaging in conversations with peers advancing new approaches to radiopharmaceuticals, imaging agents, and detection technologies to improve the treatment of cancer and other serious diseases this week at the 37th Annual Congress of the European Association of Nuclear Medicine (EANM). #MarianaOnTheMove #Oncology #RadioligandTherapies #RLT

Visit our poster today at the 36th EORTC - European Organisation for Research and Treatment of Cancer-National Cancer Institute (NCI)-American Association for Cancer Research Symposium where we’re sharing preclinical data that confirms our DLL3-targeted radioligand therapy is active against DLL3, including in tumor models exhibiting low DLL3 expression. The results further support its potential to address a range of solid tumor indications as a novel treatment option. (Poster ENA24-152) #ENA2024 #RLT #radioligandtherapy #oncology

Our novel, DLL3-targeted radioligand therapy is designed for potential high, rapid tumor uptake and retention, and fast clearance of unbound molecules. Today at the ESMO - European Society for Medical Oncology Congress 2024, we’re presenting preclinical results that characterize?in vitro?and?in vivo?properties of our experimental treatment. (Poster #1153P) #ESMO2024 #RLT #radioligandtherapy #oncology?

Mariana Oncology today announced the company will be acquired by Novartis for up to $1.75B. Together, we will accelerate the development and delivery of precision radioligand therapeutics – therapies with the potential to transform the standard of care for people living with cancer. Read more about the exciting news here: https://lnkd.in/geVhN7RG

Meet the visionary force behind our scientific endeavors, Alonso Ricardo! As our Chief Scientific Officer, he brings cutting-edge expertise and innovation to our research journey. ? Alonso has over a decade of drug discovery and development experience leading scientific programs across multiple therapeutic programs including immunology, metabolic diseases, and oncology. ? We are glad to have you on #TeamMariana, Alonso. Your commitment is truly appreciated! ? Stay tuned for more leadership team spotlights!

Did you know that the choices we make every day can lower our risk for different types of #cancer? Research shows that up to 50% of cancer cases and about 50% of cancer deaths are preventable with the knowledge we have today. ? At Mariana, we are not only dedicated to transforming cancer treatment, but the experience of cancer care for people living with this disease, helping to maintain quality of life throughout a person’s cancer journey. Learn more here: www.marianaoncology.com ? And join us in celebrating #NationalCancerPreventionMonth by learning more about how to reduce your cancer risk and detect cancer early. Visit https://lnkd.in/gT2vd6hZ